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Using a preparation of purified human T lymphocytes, we were able to resolve a partially purified protein kinase C (PKC) 
enzyme fraction into two distinct subspecies, of approximately equal activity. Biochemical and immunocytochemical 
analysis revealed that these fractions closely resembled the type II(B) and type III(a) PKC subspecies previously identified 
and characterised from brain tissue. These results provide valuable information for further studies on the role of individu- 
al PKC subspecies in T lymphocyte proliferation. 
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1. INTRODUCTION 
Information transduction into cells via the bifur- 
cating signal pathway involving calcium mobiliza- 
tion and PKC activation is a mechanism utilized by 
a large number of hormones, neurotransmitters 
and growth factors (reviews [l-3]). The diverse 
physiological responses that can be promoted by 
such a variety of stimuli acting through a common 
pathway appears to result, in part, from molecular 
heterogeneity within the individual components of 
the signal transduction machinery. For PKC, 
realisation of this phenomenon occurred relatively 
recently, and can be attributed primarily to mole- 
cular cloning analysis of the enzymes isolated from 
the brain tissue of several mammalian species (see 
[4] for references to molecular cloning studies, and 
also [5-71. PKC is now known to exist as a family 
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of multiple subspecies, which may be provisionally 
grouped according to common structural features 
[7,8]. The complete primary structures of one 
group of subspecies, having my-, PI-, PII- and y- 
sequences, have been deduced by analysis of the 
cDNA sequences obtained from brain and spleen 
libraries. These sequences have been shown to en- 
code the enzyme fractions designated type I(y), 
type II@1 +,&I) and type III(a), resolved from a 
purified preparation of rat brain enzyme by 
hydroxyapatite column chromatography [9- 111. 
(The system of nomenclature used herein for the 
PKC subspecies has been explained previously [8], 
as have the experimental approaches that allowed 
the identification of the cDNA clones that corres- 
pond to the enzyme fractions resolved from rat 
brain by hydroxyapatite column chromatography 
[lo-121.) In addition, a second group of enzyme 
subspecies, designated 6, E and f, have been iden- 
tified [4,7], that are closely related to, but clearly 
different from, the first group. The enzyme 
subspecies that comprise the known PKC enzyme 
family appear to have a slightly different mode of 
activation and to exhibit a differential distribution 
among various tissues and cells [12-191. These 
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properties per se are likely to be important factors 
in determining the functional specificity of the en- 
zyme within particular cell types. 
In human T lymphocytes, activation of PKC by 
either phorbol ester or diacylglycerol analogues 
has been shown to act synergistically with calcium 
ionophore to induce cell proliferation [20-221. 
Human T lymphocytes represent, therefore, a con- 
venient non-clonal cell type suitable as a model for 
studying the role of the individual PKC subspecies 
in the molecular events underlying cell prolifera- 
tion. As a preliminary approach to such studies, 
this paper reports a biochemical and im- 
munocytochemical investigation of the PKC 
subspecies expressed in a pure population of 
resting human T lymphocytes. 
2. MATERIALS AND METHODS 
2.1. Materials and chemicals 
Calf thymus Hl histone was prepared as previously described 
[23]. Phosphatidylserine and 1,2-diolein were from Serdary 
Research Laboratories. [y-“P]ATP was purchased from 
Amersham. 
2.2. Purification of human T lymphocytes from whole blood 
Peripheral venous blood (400 ml) was collected from healthy 
volunteers and depleted of erythrocytes by mixing with 
0.75 vols of 1% (w/v) dextran in normal saline and incubating 
at room temperature for 45 min. Mononucleocytes were then 
separated by centrifugation of the plasma over Ficoll-Hypaque 
(Nycomed, Norway) and depleted of B lymphocytes and 
macrophages, firstly, by passage through a nylon wool column, 
as described by Dixon and Uyemura [24] (except that all pro- 
cedures were carried out at room temperature), and then by in- 
cubation in plastic culture dishes (2 x 10’ cells/dish) containing 
20 ml RPM1 1640 (Gibco) and 10% (v/v) autologous serum, for 
30 min at room temperature. Finally, the T lymphocyte 
preparation was treated with T cell ‘Lymphokwik’ (One Lamb- 
da Inc., CA), at 1 x 10’ cells/O.8 ml reagent, to eliminate con- 
taminating B lymphocytes, macrophages, granulocytes and 
pre-activated T lymphocytes. Using this method, 400 ml of 
blood yielded approx. 5 x 10’ resting T lymphocytes, that were 
>99% positive for the CD3 antigen and 0% positive for the 
HLA-DR antigen, as determined by immunocytochemical 
staining with the appropriate monoclonal antibodies. Likewise, 
immunocytochemical staining revealed that the preparation 
consisted of approx. 60% CD4 antigen positive cells and 40% 
CD8 antigen positive cells. 
2.3. Partial purification of PKC from human T lymphocytes 
All procedures were carried out at 4°C unless otherwise 
stated. The preparations of purified T lymphocytes (approx. 5 
x 10’ cells) were washed once in 10 ml of 20 mM Tris-HCI (pH 
7.5 at room temperature), containing 0.25 M sucrose, 10 mM 
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EGTA, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride 
(PMSF) and 20gg/ml leupeptin, before being disrupted by 
sonication on ice (4 x 15 s; Kontes cell disrupter) in 5 ml of the 
same buffer (pH 7.5 at 4”C), and then homogenized using a 
Potter-Elvejhem-type teflon/glass homogenizer. The homoge- 
nate was centrifuged at 1500 x g for 10 min, and the pellet was 
resuspended in 2 ml of the buffer and re-centrifuged as above. 
The supernatant fractions from these two steps were pooled, 
and the buffer was adjusted to 1% (v/v) Triton X-100. The 
suspension was stirred for 30 min at 4”C, sonicated (4 x 15 s), 
and then centrifuged at 100000 x g for 30 min. The supernatant 
from this centrifugation step was then applied to a TSKgel 
DEAE-5PW column (0.75 x 7.5 cm, Toyo Soda, Tokyo) con- 
nected to an FPLC system (Pharmacia), that had been pre- 
equilibrated with 20 mM Tris-HCI at pH 7.5, containing 
0.5 mM EGTA, 0.5 mM EDTA and 10 mM 2-mercaptoethanol 
(buffer A). Protein was eluted from the column by the applica- 
tion of a linear concentration gradient of NaCl in buffer A 
(O-400 mM NaCl, in 20 ml buffer), at a flow rate of 0.5 ml/ 
min. Fractions (0.5 ml) were collected and assayed for PKC ac- 
tivity as described below. The fractions containing PKC activity 
were pooled (see fig.lA), and then subjected to chromatog- 
raphy on a hydroxyapatite column (0.78 x 10 cm, type S, 
Koken Co. Ltd, Tokyo), as described previously [25]. For 
characterisation of the enzyme subspecies that were eluted from 
the hydroxyapatite column, the fractions containing peak en- 
zyme activity were pooled and dialyzed against buffer A con- 
taining 10% (v/v) glycerol. 
2.4. Assay of PKC activity 
Enzyme activity was assayed by measuring the incorporation 
of ‘*Pi into Hl histone from [y-32P]ATP, as described previous- 
ly [15]. To the standard reaction mixture were added 
8-20 pg/ml phosphatidylserine, 0.8-2 /g/ml 1,2-diolein and 
calcium chloride (as indicated), and 20~1 enzyme fractions. 
Non-PKC kinase activity was measured by replacing 
phospholipid with 20 mM Tris-HCl, and by replacing calcium 
chloride with 0.5 mM EGTA. 
2.5. Immunocytochemical staining of human T lymphocytes 
Paraformaldehyde (0.05%, w/v) fixed, Triton X-100 (O.l%, 
v/v) permeabilized cells were subjected to immunocytochemical 
staining with polyclonal antibodies raised against synthetic 
oligopeptides. The polyclonal antibodies designated CKpVSPI- 
a, CKpVSflII-a and CKpClLu-a, were prepared against the 
sequence-specific oligopeptides SYTNPEFVINV (type II(&) 
enzyme subspecies, residues 661-671, Cd-V5 region), 
SFVNSEFLKPEVKS (type II@II) enzyme subspecies, residues 
660-673, Cd-VS region) and VYPANDSTASQDVANR (type 
III@) enzyme subspecies residues 4-19, Vi region), respective- 
ly. Incubation with these antibodies was carried out overnight 
at 4”C, in 0.1 M Tris-HC1 at pH 7.6, containing 4% (v/v) nor- 
mal human serum, at a dilution that produced no positive im- 
munoreaction when the antibodies had been pre-adsorbed by 
the appropriate peptide. Immunoreactive material was subse- 
quently visualised using an anti-rabbit immunoglobulin strep- 
tavidin/biotin-peroxidase immunostaining kit (Biogenex, CA), 
employing 3.3 ‘-diaminobenzidine as substrate. Cells were final- 
ly washed, dehydrated, mounted in Entellan (Merck), and 
photographed under a Nikon Optiphot microscope, using Fuji 
Minicopy 32 film. 
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3. RESULTS AND DISCUSSION 
3.1. Partial purification and resolution of PKC 
subspecies 
Chromatography of the T lymphocyte extract on 
a TSK gel DEAE-SPW column produced a single 
major peak of calcium- and phospholipid- 
dependent protein kinase activity (fig. 1 A), which, 
when applied to a hydroxyapatite column, could 
be resolved into two distinct enzyme fractions 
(fig.lB), eluting at approx. 90 mM (peak I) and 
130 mM (peak II) potassium phosphate concentra- 
tion, respectively. These fractions were estimated 
to contain approx. equal levels of enzyme activity 
(peak I, 49%; peak II, 51%). The resolution of on- 
ly two distinct PKC subspecies from human T lym- 
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Fig.1. Partial purification and resolution of PKC subspecies 
from human T lymphocytes. Protein kinase activity was 
assayed with 0.3 mM calcium chloride, 20 pg/ml phosphatidyl- 
serine and 2 pg/ml 1,2-diolein (0) or in the presence of 
0.5 mM EGTA (0), as described in section 2. (A) DEAE-SPW 
profile. Fraction = 0.5 ml. Shaded area subjected to chroma- 
tography on a hydroxyapatite column. (B) Hydroxyapatite 
profile. Fraction = 1.0 ml. phosphatidylserine. 
Fig.2. Activation of PKC subspecies isolated from human T 
lymphocytes by 1,2-diolein and phosphatidylserine, at various 
concentrations of calcium chloride. Protein kinase C activity 
was assayed for each enzyme subspecies in the presence of 
0.8 pg/ml 1,2-diolein (A), 8 pg/ml phosphatidylserine (0) or 
both lipids (o), at various concentrations of calcium chloride, 
as described in section 2. Where indicated with arrows, 0.5 mM 
EGTA was added instead of calcium chloride. (A) Peak I; (B) 
peak II. Data are the mean values obtained from two 
independent enzyme preparations, expressed as a percentage of 
the maximum response obtained in the presence of diolein and 
phocytes is consistent with the results of similar 
studies from this laboratory [10,11,15,19] and 
others [9,12,16], using rat brain and various other 
tissue sources. These studies reported that, 
whereas central nervous tissue expressed types I(y), 
110 and III@) enzyme subspecies, other tissues 
such as liver, spleen and kidney, expressed types 
II(@) and III(a) in varying ratios, but not type I(y). 
In this study, the concentration of potassium 
phosphate at which the two enzyme fractions from 
human T lymphocytes eluted from the hydrox- 
yapatite column was found to correspond closely 
to the type II@) and type III(a) enzyme subspecies 
from rat brain. Further analysis was needed, 
however, to confirm their identity. 
3.2. Calcium-, diacylglycerol- and phospholipid- 
sensitivity of the resolved PKC subspecies 
Fig.2 shows the calcium-dependent activation, 
in the presence of 1,2-diolein (diacylglycerol) and 
phosphatidylserine, of the peak I and peak II PKC 
enzyme fractions obtained from human T lym- 
phocytes. In the presence of 1,2-diolein alone, 
neither subspecies howed calcium-dependent pro- 
tein kinase activity toward H 1 histone. In contrast, 
in the presence of phosphatidylserine alone, both 
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Fig.3. Immunocytochemical staining of human T lymphocytes with subspecies-specific anti-PKC polyclonal antibodies. Human T 
lymphocytes were stained with polyclonal antibodies as described in section 2. (A) CKpClcu-a, anti-type III(d) antibody; (B) 
CKpV5,611-a, anti-type II@II) antibody; (C) CKpVSPI-a, anti-type II@) antibody. Control cells, where the primary antibody was 
replaced with Tris-buffered saline, did not show a positive immunoreaction. In this photograph, oil immersion was used under a x 100 
objective. Bar = 20pm. 
enzyme subspecies were activated in a calcium- 
dependent manner. Addition of 0.1 mM calcium 
ions resulted in approx. 80% of maximal activity, 
with concentrations higher than this having an in- 
hibitory effect. The addition of both 1,2-diolein 
and phosphatidylserine had a marked effect on the 
enzyme activity, and revealed a characteristic dif- 
ference between peak I and peak II enzyme frac- 
tions. The peak I enzyme activity could be 
stimulated to >60% of maximal activity in the 
nominal absence of calcium ions, whereas the peak 
II enzyme showed ~20% of maximal activity. 
With the addition of only micromolar concentra- 
tions of calcium ions, however, both enzymes 
showed nearly full activity. This mode of activa- 
tion of peak I and II enzymes is very similar to type 
II@I+,HI) and type III(a) enzyme subspecies 
purified from rat whole brain [14] and bovine 
cerebellum (Shearman, M.S., unpublished), and 
provides further evidence that the two enzyme 
subspecies isolated from human T lymphocytes are 
closely related to these brain enzymes. The 
calcium-independent activation of the type II 
enzyme subspecies in the presence of diacylglycerol 
and phosphatidylserine is of considerable interest, 
as it suggests that extracellular stimuli, which can 
promote the formation of diacylglycerol in the 
absence of calcium mobilization (for example, by 
the hydrolysis of phosphatidylcholine) may 
preferentially activate this PKC subspecies. 
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3.3. Immunocytochemical staining of human T 
lymphocytes 
The expression, in human T lymphocytes, of 
PKC subspecies corresponding to the brain type 
II@ and type III(a) enzymes was further in- 
vestigated by immunocytochemical staining of the 
cells with polyclonal antibodies raised against pep- 
tide sequences uniquely present in the deduced 
primary structure of the type 11@31), type IIQ311) 
and type III(a) enzymes (fig.3). All three of these 
antibodies gave a positive immunoreaction in the T 
lymphocytes, whilst an antibody raised against a 
peptide sequence uniquely present in the type I(y) 
PKC sequence (CKpVSy-a; DARSPTSPVPVPV, 
residues 684-696, VS region), gave no positive 
staining (not shown). For each antibody, the stain- 
ing was predominantly cytoplasmic, although 
some membrane localization was noted in the more 
intensely staining cells, and was heterogeneous 
within the T cell population. A comparison of the 
immunocytochemical staining obtained with the 
anti-PKC antibodies with that obtained with an- 
tibodies against the CD4 and CD8 antigens, sug- 
gests that the heterogeneity observed is not related 
to the helper/suppressor T lymphocyte subsets 
(Berry, N., unpublished). Western blotting 
analysis with the antibody against the type II(~311) 
enzyme subspecies has confirmed that the epitope 
against which it was raised is present in the peak I 
enzyme fraction, but not in the peak II fraction. In 
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addition, the protein containing this amino acid se- 
quence has a molecular mass very similar to that of 
the rat whole brain and bovine cerebellum type 
II@ +,611) enzymes, and is present at a much 
higher ratio than the type 11(&I) enzyme, in the 
peak I fraction. 
The results presented above show that the PKC 
activity isolated from resting human T lym- 
phocytes can be resolved into two distinct enzyme 
fractions, which - as assessed by biochemical and 
immunocytochemical criteria - correspond closely 
to type 11(&I +pII) and type III(a) PKC subspecies 
that have been previously isolated and character- 
ised from brain tissue. Partial characterisation of 
the T lymphocyte enzymes suggests that, in certain 
cellular environments, one of the subspecies may 
become preferentially activated. The possibility 
that the different enzyme subspecies may fulfil 
defined temporal or spatial functions in the 
biochemical mechanisms underlying T lymphocyte 
proliferation is an important focus of future 
studies. 
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